FDA Data Show Most Antibiotic-Contaminated Shrimp Refusals Originate from BAP-Certified Facilities
核心洞察
FDA refusal data show 79% of shrimp shipments refused for banned antibiotics in the first eight months of 2026 originated from Best Aquaculture Practices (搜索) (BAP)-certified facilities.
Nitrofurans (搜索) and chloramphenicol, which the FDA describes as carcinogenic and genotoxic, remain the primary banned veterinary drugs detected in refused shrimp imports.
The FDA updated Import Alert 16-139 to detail significant public health risks, including the spread of antimicrobial-resistant bacterial strains from antibiotic residues in aquaculture.
Analysis of U.S. Food and Drug Administration (FDA) monthly refusal data shows that 79% of shrimp shipments refused for banned antibiotics in 2026 have originated from processors operating with certifications under the Best Aquaculture Practices (搜索) (BAP) program. The finding, reported by the Southern Shrimp Alliance, raises questions about whether third-party certification audits adequately detect banned veterinary drug use at farms and processing plants.
FDA Refusal Trends in 2026
The FDA reported 50 seafood entry line refusals in August 2026, with shrimp contaminated by veterinary drug residues identified from two different countries. Through the first eight months of 2026, the countries responsible for the most entry line refusals of shrimp for veterinary drug residues are India (16), Indonesia (10), and Vietnam (10), followed by China (7) and Bangladesh (6). India, Indonesia, and Vietnam accounted for 51% of the volume of frozen shrimp imported into the United States over the first half of 2026.
The FDA refused seven entry lines of shrimp in August 2026 and reported refusing one additional entry line in July 2026 for reasons related to veterinary drug residues. Notable refusals included six entry lines from India's K.N.C. Agro Limited for nitrofurans (搜索), a BAP-certified (4-Star) facility listed on Import Alert 16-129 on June 9, 2026, as well as a breaded shrimp entry line from China's Xianmeilai Food Co., Ltd. for unsafe additive and veterinary drug residues.
The BAP Certification Gap
The Best Aquaculture Practices (搜索) (BAP) certification program, operated by the Global Seafood Alliance (搜索), is widely used by retailers and seafood brands to indicate that seafood is safe and responsibly farmed. However, 79% of shrimp entry lines refused for antibiotics in the first eight months of 2026 originated from facilities that operated with BAP certifications this year.
The shrimp entry lines refused by the FDA for banned antibiotics in 2026 originated from ten BAP-certified facilities operating in six different countries (Bangladesh, China, India, Indonesia, Thailand, and Vietnam), led by Indonesia's PT. Tamron Akuatik Produk Industri, followed by Bangladesh's Organic Shrimps Export Ltd.
In May, the Senate Health, Education, Labor, and Pensions (HELP) Committee issued letters requesting information regarding the operations of certification programs maintained by the Marine Stewardship Council, the Aquaculture Stewardship Council, and the Global Seafood Alliance (搜索). Notably, although the Marine Stewardship Council and the Aquaculture Stewardship Council have publicly released their responses to these letters, the Global Seafood Alliance has not made its response available.
FDA Details Public Health Risks of Antibiotics in Aquaculture
In August, the FDA updated Import Alert 16-139, "Detention without Physical Examination of Aquacultured Shrimp and Prawn Products in all Market Forms from Peninsular Malaysia Due to the Health Risks of Antibiotic Use in Shrimp Aquaculture," to clarify that the Import Alert applied to all shrimp originating from or shipped out of every state and federal territory in Malaysia except Sabah, Sarawak, and Labuan.
The FDA also provided a substantially more detailed accounting of the risks presented by nitrofurans (搜索) and chloramphenicol. The agency stated that "a public health concern exists regarding prolonged exposure to nitrofurans and chloramphenicol, broad-spectrum antimicrobial drugs used in food-producing animals," noting that these compounds "are known to have carcinogenic and genotoxic properties."
The FDA further warned that "the introduction of these residues into the food supply can contribute to the development and spreading of antimicrobial-resistant (AMR) bacterial strains. These resistant pathogens may be transferred to and cause infections in humans, compromising the effectiveness of critical antimicrobial treatments vital to human medicine."
The agency determined that "using nitrofurans (搜索) or chloramphenicol at any life stage of an animal results in residues in the final edible products," and that the presence of these residues in processed shrimp or prawns renders the food adulterated under the FD&C Act. The FDA has not approved any new animal drug application, conditional approval, or index listing for the use of nitrofurans or chloramphenicol in shrimp or prawns.
Broader Regulatory Actions
In addition to refusals for veterinary drug residues, the FDA reported refusing an entry line of shrimp from the Indian exporter Ananda Enterprises (India) Private Limited for "added bulk" on August 16, 2026. The FDA added Ananda Enterprises to Import Alert 99-47, "Detention Without Physical Examination of Human Food Products That Appear to be Adulterated for Economic Gain," on July 16, 2026, because its shrimp shipments "appear to have a substance added to, mixed or packed with it so as to increase its bulk or weight, or reduce its quality or strength, or make it appear better or of greater value than it is." Ananda Enterprises holds numerous BAP certifications for hatcheries, farms, feed mills, and its processing plant (P10372; 4-Star).
The FDA's 2026 year-to-date total of shrimp entry line refusals for veterinary drug residues stands at 56, compared with 93 for the full year 2025, which represented the sixth highest total in 24 years.